Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders. Our most advanced candidate is a non-steroidal selective androgen receptor modulator (SARM) currently in Phase 2 trial for the treatment recovery from hip fracture surgery. Our thyroid receptor beta (TRb) agonist platform, also in Phase 2, is being developed for lipid disorders such as hypercholesterolemia and fatty liver diseases such as non-alcoholic steatohepatitis (NASH) as well as for rare diseases of glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy, or X-ALD. See more at http://www.vikingtherapeutics.com



Ligand Pharmaceuticals

Aspire Capital Partners LLC

Viking Therapeutics, Inc.

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

Google Tag Manager

HSTS

Google Font API

Google Analytics

Google Maps

WordPress

Global Site Tag

President and Chief Executive Officer

Brian Lian

General Counsel

Chase Leavitt

Chief Financial Officer

Greg Zante

Senior Vice President, HR

Anita Wiseth

SVP, Clinical Operations

Marianne Mancini

Vice President, Finance and Administration

Mike Morneau

Director, Pharmaceutical Development

Amber Weissenfluh

Senior Director, Pharmacology

Kader Yagiz

Non Executive Director

Kathy Rouan

Maureen Barnes

Michel Moreau

CEO & President

Therapeutics Companies that Exited

Health Care Companies With More Than 10 Employees (Top 10K)

Therapeutics Companies (Top 10K)

Western US Companies With Fewer Than 1000 Employees (Top 10K)

Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK0612, a first-in-class, orally available drug candidate type 2 diabetes. The Company’s second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia. Viking is also developing three novel preclinical programs targeted at metabolic diseases and anemia.

Post-IPO Equity - Viking Therapeutics

Debt Financing - Viking Therapeutics

Computer and Software Services and Scientific Services

San Diego

California

United States

North America

Viking Therapeutics

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?

Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

Is Viking Therapeutics a Buy on the Dip?

The week in pharma: action, reaction and insight – week to November 8

Viking Therapeutics Director Sells 2,000 Shares

4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move

An orally available small molecule thyroid hormone receptor beta agonist for treating lipid and metabolic disorders, including non-alcoholic steatohepatitis (NASH).

A dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for treating metabolic disorders such as obesity.

An orally available small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).

An orally available inhibitor of fructose-1,6-bisphosphatase for the potential treatment of type 2 diabetes.

A diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitor in development for treating metabolic disorders such as hypertriglyceridemia and NASH.

An orally available, non-steroidal selective androgen receptor modulator (SARM) for treating patients recovering from non-elective hip fracture surgery.

United Kingdom

Europe

Slovenia

Belgium

Germany

HTML5

Valimail

Apache Server

Microsoft Outlook

jQuery

Google Fonts

Bootstrap

Vimeo

F5 NGINX

Office 365

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.

Madrigal Pharmaceuticals

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of liver diseases and metabolic disorders.

Galmed Pharmaceuticals

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of chronic liver diseases.

Intercept Pharmaceuticals

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Its lead drug candidate, VK2809, is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis and NAFLD. The company also has other drug candidates in various stages of development for different conditions.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

news impact assignment basic	general	Feb 27, 2024 7:04 PM	3f9c252a
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 27, 2024 7:04 PM	168cda68
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	bd6b3e95
crunchbase profile	general	Nov 19, 2024 11:28 AM	8f845229
li profile	general	Feb 27, 2024 7:04 PM	787948b4
translate crunchbase fundingrounds	general	Nov 19, 2024 1:28 PM	19fd5698
peers	general
news basic	general	Feb 27, 2024 7:04 PM	9f8fe396
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:VIKINGTHERAPEUTICS

Viking Therapeutics, Inc.

Last Close

51.63

22/11 21:00

Market Cap

6.39B

Beta: -

Volume Today

2.63M

Avg: -